Revolution Medicines Q3 net loss $108.4M; updates on RMC-6236, RMC-6291; EQRx close imminent

Revolution Medicines, Inc.

2023-Q3 EPS reported -$2.65 revenue$10,838,000

Q3 2023 net loss $108.4M vs $73.3M; revenue $0 vs $3.4M; R&D spend $107.7M (+55%).
Cash $813.2M; updated FY2023 net loss guidance $385-$415M; cash runway into 2025.
Promising clinical data for RMC-6236 (RAS MULTI) and RMC-6291 (RAS G12C); Phase 3 plans for NSCLC and PDAC in 2024.
EQRx acquisition expected to close Nov 2023; all-stock deal, ~55M shares issued, adds ~$1.1B net cash (~$20/share issued).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revolution Medicines, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 6, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-059374

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.